CN114672559A - 癌症对通过pd-1阻断实现的免疫疗法响应的决定因素 - Google Patents

癌症对通过pd-1阻断实现的免疫疗法响应的决定因素 Download PDF

Info

Publication number
CN114672559A
CN114672559A CN202210026426.9A CN202210026426A CN114672559A CN 114672559 A CN114672559 A CN 114672559A CN 202210026426 A CN202210026426 A CN 202210026426A CN 114672559 A CN114672559 A CN 114672559A
Authority
CN
China
Prior art keywords
cancer
immune checkpoint
response
mutation
checkpoint modulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210026426.9A
Other languages
English (en)
Chinese (zh)
Inventor
T·A·陈
N·A·里兹维
M·D·赫尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CN114672559A publication Critical patent/CN114672559A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202210026426.9A 2014-11-21 2015-11-23 癌症对通过pd-1阻断实现的免疫疗法响应的决定因素 Pending CN114672559A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462083088P 2014-11-21 2014-11-21
US62/083,088 2014-11-21
US201562132381P 2015-03-12 2015-03-12
US62/132,381 2015-03-12
PCT/US2015/062208 WO2016081947A2 (en) 2014-11-21 2015-11-23 Determinants of cancer response to immunotherapy by pd-1 blockade
CN201580073049.2A CN107206064B (zh) 2014-11-21 2015-11-23 癌症对通过pd-1阻断实现的免疫疗法响应的决定因素

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580073049.2A Division CN107206064B (zh) 2014-11-21 2015-11-23 癌症对通过pd-1阻断实现的免疫疗法响应的决定因素

Publications (1)

Publication Number Publication Date
CN114672559A true CN114672559A (zh) 2022-06-28

Family

ID=56014697

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210026426.9A Pending CN114672559A (zh) 2014-11-21 2015-11-23 癌症对通过pd-1阻断实现的免疫疗法响应的决定因素
CN201580073049.2A Active CN107206064B (zh) 2014-11-21 2015-11-23 癌症对通过pd-1阻断实现的免疫疗法响应的决定因素

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580073049.2A Active CN107206064B (zh) 2014-11-21 2015-11-23 癌症对通过pd-1阻断实现的免疫疗法响应的决定因素

Country Status (9)

Country Link
US (3) US20180291074A1 (enExample)
EP (2) EP4393546A3 (enExample)
JP (4) JP7173733B2 (enExample)
CN (2) CN114672559A (enExample)
AU (3) AU2015349644B2 (enExample)
CA (1) CA2968059A1 (enExample)
HK (1) HK1244440A1 (enExample)
MA (1) MA40737A (enExample)
WO (1) WO2016081947A2 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
PL3081576T3 (pl) 2013-12-12 2020-03-31 Shanghai Hengrui Pharmaceutical Co., Ltd. Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne
LT3212670T (lt) 2014-10-29 2021-02-10 Five Prime Therapeutics, Inc. Kombinuotasis vėžio gydymas
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
CA3008641A1 (en) 2015-12-16 2017-06-22 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
KR102500659B1 (ko) 2016-02-29 2023-02-16 제넨테크, 인크. 암에 대한 치료 및 진단 방법
CN109476731A (zh) 2016-02-29 2019-03-15 基础医药有限公司 治疗癌症的方法
CN109069078A (zh) * 2016-03-01 2018-12-21 北卡罗来纳州立大学 通过微针贴片辅助的递送增强癌症免疫疗法
AU2017227308B2 (en) 2016-03-02 2024-02-22 Toray Industries, Inc. Immunity inducer
TWI895621B (zh) 2016-05-27 2025-09-01 美商艾吉納斯公司 抗-tim-3抗體及其使用方法
WO2018003995A1 (ja) * 2016-07-01 2018-01-04 国立大学法人東北大学 免疫チェックポイント阻害薬使用における免疫関連副作用の予測方法
KR20190038935A (ko) 2016-08-25 2019-04-09 난토믹스, 엘엘씨 면역요법 마커들 및 그 용도들(immunotherapy markers and uses therefor)
JP7579056B2 (ja) * 2016-10-06 2024-11-07 ジェネンテック， インコーポレイテッド がんのための治療方法及び診断方法
CA3039402A1 (en) 2016-10-07 2018-04-12 Omniseq, Inc. Methods and systems for determining personalized therapies
WO2018132753A1 (en) * 2017-01-13 2018-07-19 Nantbio, Inc. Validation of neoepitope-based treatment
US12331359B2 (en) 2017-01-18 2025-06-17 Michael Laessig Neoantigens and uses thereof for treating cancer
US20190351039A1 (en) 2017-02-01 2019-11-21 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
WO2018145023A1 (en) * 2017-02-06 2018-08-09 Novartis Ag Method of predicting response to immunotherapy
EP3494235A1 (en) * 2017-02-17 2019-06-12 Stichting VUmc Swarm intelligence-enhanced diagnosis and therapy selection for cancer using tumor- educated platelets
CN110651036A (zh) * 2017-03-20 2020-01-03 健诺西生物科学公司 治疗方法
CA3058175A1 (en) * 2017-03-31 2018-10-04 Bristol-Myers Squibb Company Methods of treating tumor
GB201710815D0 (en) * 2017-07-05 2017-08-16 Francis Crick Inst Ltd Method
AU2018304458B2 (en) * 2017-07-21 2021-12-09 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
WO2019023624A1 (en) * 2017-07-28 2019-01-31 Bristol-Myers Squibb Company PREDICTIVE PERIPHERAL BLOOD BIOMARKER FOR INHIBITORS OF CONTROL POINTS
KR20200051024A (ko) * 2017-09-13 2020-05-12 파이브 프라임 테라퓨틱스, 인크. 췌장암에 대한 조합 항-csf1r 및 항-pd-1 항체 조합 요법
US20200268831A1 (en) * 2017-09-15 2020-08-27 The Texas A&M University System Methods for enhancing immunotherapy in the treatment of cancer
CN117987553A (zh) * 2017-09-25 2024-05-07 纪念斯隆凯特琳癌症中心 肿瘤突变负荷和检查点免疫疗法
EP3691676A4 (en) * 2017-10-02 2021-06-16 Curematch, Inc. METHOD FOR PREDICTING ANTIGENICITY AND / OR IMMUNOGENICITY OF A TUMOR-DERIVED NEO-PEPTIDE, USING MUTATIONAL SIGNATURE GROUNDS
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
WO2019075251A2 (en) * 2017-10-12 2019-04-18 Nantomics, Llc CANCER SCORE FOR EVALUATION AND PREDICTION OF RESPONSE FROM BIOLOGICAL FLUIDS
JP2020536894A (ja) 2017-10-15 2020-12-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 腫瘍処置法
EP3704268B1 (en) 2017-11-03 2025-01-22 Guardant Health, Inc. Normalizing tumor mutation burden
EP3710600B1 (en) * 2017-11-17 2025-03-12 GMDx Co Pty Ltd Systems and methods for predicting the efficacy of cancer therapy
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
JP7299169B2 (ja) * 2017-12-01 2023-06-27 イルミナ インコーポレイテッド 体細胞突然変異のクローン性を決定するための方法及びシステム
EP3788173B1 (en) * 2018-05-03 2023-11-29 F. Hoffmann-La Roche AG Surrogate marker and method for tumor mutation burden measurement
JP2021522298A (ja) * 2018-05-04 2021-08-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 癌治療のためのＰＤ−１／ＰＤ−Ｌ１、ＴＧＦβおよびＤＮＡ−ＰＫの同時阻害
CA3107983A1 (en) 2018-07-23 2020-01-30 Guardant Health, Inc. Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage
EP3830296A1 (en) 2018-07-27 2021-06-09 F. Hoffmann-La Roche AG Method of monitoring effectiveness of immunotherapy of cancer patients
JPWO2020045479A1 (ja) * 2018-08-29 2021-08-12 公益財団法人東京都医学総合研究所 ＨＧＦ−ｒｅｇｕｌａｔｅｄ ｔｙｒｏｓｉｎｅ ｋｉｎａｓｅ ｓｕｂｓｔｒａｔｅ（ＨＧＳ）を標的とした抗腫瘍剤
SG11202101400UA (en) 2018-08-31 2021-03-30 Guardant Health Inc Microsatellite instability detection in cell-free dna
AU2019379167A1 (en) 2018-11-15 2021-06-03 Personal Genome Diagnostics Inc. Method of improving prediction of response for cancer patients treated with immunotherapy
CN113194995A (zh) * 2018-12-12 2021-07-30 免疫医疗有限责任公司 基于血液的肿瘤突变负荷预测非小细胞肺癌的总存活
WO2020252456A1 (en) 2019-06-14 2020-12-17 The Trustees Of Columbia University In The City Of New York Nt5c2 inhibitors for the treatment of chemotherapy-resistant acute lymphoblastic leukemia
EP4051314A4 (en) * 2019-11-01 2023-12-06 Memorial Sloan Kettering Cancer Center HLA CLASS I SEQUENCE DIVERGENCE AND CANCER THERAPY
GB202003669D0 (en) * 2020-03-13 2020-04-29 Univ Oxford Innovation Ltd Method for identifying neo-antigens
EP4143345A1 (en) * 2020-04-28 2023-03-08 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
EP4158070A4 (en) * 2020-06-01 2025-05-07 GMDx Co Pty Ltd METHODS FOR PREDICTING CANCER PROGRESSION
CN112309502B (zh) * 2020-10-14 2024-09-20 深圳市新合生物医疗科技有限公司 一种计算肿瘤新抗原负荷的方法及系统
WO2022099004A1 (en) * 2020-11-06 2022-05-12 The General Hospital Corporation Methods for characterizing biological samples
US20240238340A1 (en) * 2021-05-03 2024-07-18 Rutgers, The State University Of New Jersey Immunotherapy for inflammatory bowel disease and/or cancer
CN113030475B (zh) * 2021-05-25 2021-08-10 泛肽生物科技(浙江)有限公司 一种基于细胞线粒体质量评估的t细胞pd-1检测方法
CN113355424B (zh) * 2021-07-14 2022-03-25 江苏先声医学诊断有限公司 Pcdh11x突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用
WO2024216165A1 (en) 2023-04-12 2024-10-17 Icahn School Of Medicine At Mount Sinai Computational methods for selecting personalized neoantigen vaccines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102905721A (zh) * 2010-03-19 2013-01-30 伊玛提克斯生物技术有限公司 基于avl9的癌症的诊断及治疗

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033497A1 (en) 2002-08-13 2004-02-19 Alarcon-Riquelme Marta E. Polymorphisms of PD-1
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
CA2779843A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
BR112012026227A2 (pt) * 2010-04-13 2020-08-04 Celldex Therapeutics, Inc. anticorpo monoclonal humano ou humanizado, molécula biespecífica, vetor de expressão, célula transformada, composição, e, usos de um anticorpo
PT3023788T (pt) * 2010-05-14 2020-05-18 Massachusetts Gen Hospital Composições de neoantigénios específicos de tumor para utilização no tratamento de tumores
US20130225433A1 (en) * 2012-02-29 2013-08-29 The Regents Of The Universitys Of Michagan Prostate cancer markers and uses thereof
SG11201406592QA (en) 2012-05-04 2014-11-27 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
ES2737757T3 (es) * 2012-09-28 2020-01-15 Univ Connecticut Identificación de epítopos protectores contra tumores para el tratamiento de cánceres
SG10201805674YA (en) * 2014-01-02 2018-08-30 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
KR20170080697A (ko) * 2014-11-13 2017-07-10 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
MA40737A (fr) * 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
CN117987553A (zh) * 2017-09-25 2024-05-07 纪念斯隆凯特琳癌症中心 肿瘤突变负荷和检查点免疫疗法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102905721A (zh) * 2010-03-19 2013-01-30 伊玛提克斯生物技术有限公司 基于avl9的癌症的诊断及治疗

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALEXANDRA SNYDER ET AL: "Genetic Basis for clinical response to CTLA-4 Blockade in Melanoma", 《NEW ENGLAND JOURNAL OF MEDICINE》, vol. 371, no. 23, 19 November 2014 (2014-11-19), pages 2189 - 2199, XP055262135, DOI: 10.1056/NEJMoa1406498 *

Also Published As

Publication number Publication date
EP4393546A3 (en) 2024-12-11
WO2016081947A4 (en) 2016-09-09
JP2024125234A (ja) 2024-09-13
JP2018502828A (ja) 2018-02-01
AU2021215099A1 (en) 2021-08-26
EP3220950A4 (en) 2018-08-29
WO2016081947A3 (en) 2016-07-07
AU2015349644A1 (en) 2017-06-15
MA40737A (fr) 2017-07-04
CA2968059A1 (en) 2016-05-26
JP2020196732A (ja) 2020-12-10
US20210308241A1 (en) 2021-10-07
US12485162B2 (en) 2025-12-02
AU2024278364A1 (en) 2025-02-13
CN107206064B (zh) 2021-12-21
US20180291074A1 (en) 2018-10-11
US20200040049A1 (en) 2020-02-06
HK1244440A1 (zh) 2018-08-10
JP7550193B2 (ja) 2024-09-19
JP2023055625A (ja) 2023-04-18
WO2016081947A2 (en) 2016-05-26
US10993998B2 (en) 2021-05-04
JP7173733B2 (ja) 2022-11-16
EP3220950A2 (en) 2017-09-27
AU2015349644B2 (en) 2021-08-19
EP4393546A2 (en) 2024-07-03
CN107206064A (zh) 2017-09-26

Similar Documents

Publication Publication Date Title
US12485162B2 (en) Determinants of cancer response to immunotherapy by pd-1 blockade
Sayles et al. Genome-informed targeted therapy for osteosarcoma
RU2707530C2 (ru) Детерминанты ответа раковой опухоли на иммунотерапию
US20220340663A1 (en) Tumor mutational load
US11274342B2 (en) Systems and methods for sequencing T cell receptors and uses thereof
JP2020525030A (ja) 癌の免疫療法への適合性を評価する方法
US20220389102A1 (en) Hla class i sequence divergence and cancer therapy
CN115135386A (zh) 用于治疗胶质母细胞瘤的方法
HK40115175A (en) Determinants of cancer response to immunotherapy by pd-1 blockade
You et al. Comprehensive Immune Landscape and Molecular Characteristics of Clinical Responses to Chemotherapy, Antiangiogenic Agents and PD-1 Inhibitors in Advanced Nasopharyngeal Cancer
HK40032690A (en) Tumor mutational load and checkpoint immunotherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination